scholarly journals Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures

Diagnostics ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 398
Author(s):  
Mohammad Naghavi-Behzad ◽  
Charlotte Bjerg Petersen ◽  
Marianne Vogsen ◽  
Poul-Erik Braad ◽  
Malene Grubbe Hildebrandt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Survival Time ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Standardized Uptake Value ◽  
Metastatic Breast ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Time Point

This study aimed to compare the prognostic value of quantitative measures of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) for the response monitoring of patients with metastatic breast cancer (MBC). In this prospective study, 22 patients with biopsy-verified MBC diagnosed between 2011 and 2014 at Odense University Hospital (Denmark) were followed up until 2019. A dual-time-point FDG-PET/CT scan protocol (1 and 3 h) was applied at baseline, when MBC was diagnosed. Baseline characteristics and quantitative measures of maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), corrected SUVmean (cSUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and corrected TLG (cTLG) were collected. Survival time was analyzed using the Kaplan–Meier method and was regressed on MTV, TLG, and cTLG while adjusting for clinicopathological characteristics. Among the 22 patients included (median age: 59.5 years), 21 patients (95%) died within the follow-up period. Median survival time was 29.13 months (95% Confidence interval: 20.4–40 months). Multivariable Cox proportional hazards regression analyses of survival time showed no influence from the SUVmean, cSUVmean, or SUVmax, while increased values of MTV, TLG, and cTLG were significantly associated with slightly higher risk, with hazard ratios ranging between 1.0003 and 1.004 (p = 0.007 to p = 0.026). Changes from 1 to 3 h were insignificant for all PET measures in the regression model. In conclusion, MTV and TLG are potential prognostic markers for overall survival in MBC patients.

scholarly journals FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0199529 ◽  
Author(s):  
Edouard Depardon ◽  
Salim Kanoun ◽  
Olivier Humbert ◽  
Aurélie Bertaut ◽  
Jean-Marc Riedinger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Systemic Therapy ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
First Line ◽  
Pet Ct ◽  
Eortc Criteria ◽  
Prognostic Stratification ◽  
Fdg Pet Ct

18F-FDG PET/CT in a Case of Metastatic Breast Cancer to the Vulva

2019 ◽  
Vol 44 (7) ◽  
pp. 572-573
Author(s):  
Priscilla Guglielmo ◽  
Mariachiara Paderno ◽  
Federica Elisei ◽  
Luca Guerra ◽  
Claudio Landoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 308P FDG-PET/CT versus CE-CT for response monitoring in metastatic breast cancer: A prospective comparative study

2021 ◽  
Vol 32 ◽  
pp. S498
Author(s):  
M. Vogsen ◽  
F. Harbo ◽  
N.M. Jakobsen ◽  
H.J. Nissen ◽  
S.E. Dahlsgaard-Wallenius ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Comparative Study ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Response Monitoring ◽  
Pet Ct ◽  
Prospective Comparative Study ◽  
Fdg Pet Ct

scholarly journals Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer

2016 ◽  
Vol 3 ◽  
Author(s):  
Dorothée Goulon ◽  
Hatem Necib ◽  
Brice Henaff ◽  
Caroline Rousseau ◽  
Thomas Carlier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Quantitative Evaluation ◽  
Fdg Pet ◽  
Therapeutic Response ◽  
Metastatic Breast ◽  
Pet Ct ◽  
Fdg Pet Ct

Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study

2011 ◽  
Vol 39 (3) ◽  
pp. 450-460 ◽  
Author(s):  
Nina Mortazavi-Jehanno ◽  
Anne-Laure Giraudet ◽  
Laurence Champion ◽  
Florence Lerebours ◽  
Elise Le Stanc ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Pilot Study ◽  
Endocrine Therapy ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review

Diagnostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 106 ◽  
Author(s):  
Fredrik Helland ◽  
Martine Hallin Henriksen ◽  
Oke Gerke ◽  
Marianne Vogsen ◽  
Poul Flemming Høilund-Carlsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Metastatic Breast Cancer ◽  
Solid Tumors ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Response Evaluation ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Fdg Pet Ct

18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used for response evaluation in metastatic breast cancer (MBC). In this study, we aimed to review literature comparing the PET Response Criteria in Solid Tumors (PERCIST) with Response Evaluation Criteria in Solid Tumors (RECIST) in patients with MBC. We made a systematic search in Embase, PubMed/Medline, and Cochrane Library using a modified PICO model. The population was MBC patients and the intervention was PERCIST or RECIST. Quality assessment was performed using the QUADAS-2 checklist. A total of 1975 articles were identified. After screening by title/abstract, 78 articles were selected for further analysis of which 2 duplicates and 33 abstracts/out of focus articles were excluded. The remaining 43 articles provided useful information, but only one met the inclusion and none of the exclusion criteria. This was a retrospective study of 65 patients with MBC showing one-year progression-free survival for responders versus non-responders to be 59% vs. 27% (p = 0.2) by RECIST compared to 64% vs. 0% (p = 0.0001) by PERCIST. This systematic literature review identified a lack of studies comparing the use of RECIST (with CE-CT) and PERCIST (with FDG-PET/CT) for response evaluation in metastatic breast cancer. The available sparse literature suggests that PERCIST might be more appropriate than RECIST for predicting prognosis in patients with MBC.

Sign in / Sign up

Export Citation Format

Share Document